Real-world effectiveness of benralizumab in US subspecialist-treated adults with severe asthma: Findings from CHRONICLE
Authors:
- Reynold A. PanettieriRPReynold A. Panettieri
- Njira LugogoNLNjira Lugogo
- Wendy C. MooreWMWendy C. Moore
- Bradley E. ChippsBCBradley E. Chipps
- Brett JepsonBJBrett Jepson
- Wenjiong ZhouWZWenjiong Zhou
- Christopher S. AmbroseCAChristopher S. Ambrose
- Eduardo GenofreEGEduardo Genofre
- Donna D. CarstensDCDonna D. Carstens
Open Access
- 7 June 2023
- journal article
- research article
- Published by Elsevier in Respiratory Medicine
- Vol. 216, 107285
Abstract
No abstract availableKeywords
Funding Information
- AstraZeneca
This publication has 22 references indexed in Scilit:
- Randomised controlled trials in severe asthma: selection by phenotype or stereotypeEuropean Respiratory Journal, 2018
- Healthcare resource use and costs of severe, uncontrolled eosinophilic asthma in the UK general populationThorax, 2017
- Oral Glucocorticoid–Sparing Effect of Benralizumab in Severe AsthmaNew England Journal of Medicine, 2017
- Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trialThe Lancet, 2016
- Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trialThe Lancet, 2016
- Management of the patient with eosinophilic asthma: a new era beginsERJ Open Research, 2015
- The prevalence of severe refractory asthmaJournal of Allergy and Clinical Immunology, 2015
- International ERS/ATS guidelines on definition, evaluation and treatment of severe asthmaEuropean Respiratory Journal, 2013
- MEDI-563, a humanized anti–IL-5 receptor α mAb with enhanced antibody-dependent cell-mediated cytotoxicity functionJournal of Allergy and Clinical Immunology, 2010
- Distinguishing severe asthma phenotypesJournal of Allergy and Clinical Immunology, 2004